@article {BalucaniP07.250作者= {Clotilde Balucani和凡妮莎Arnedo迪迪埃利斯和jean - louis Mas和马丁·布朗和詹姆斯Grotta和妮可·冈萨雷斯和肖恩·萨维茨和托马斯·王硕和沃纳尔和史蒂芬·莱文},title ={桥项目(弥合的差距中风管理):跨大西洋的差异管理的颈动脉狭窄(P07.250)},体积={80}={7}补充数量,页面= {P07.250——P07.250} ={2013},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:比较之间的颈动脉狭窄的态度管理欧洲(欧盟)和北美(NA)。首页背景:最优的管理(sx)症状和无症状的颈动脉狭窄(asx)仍然是有争议的,尽管临床试验评价颈动脉内膜切除术(CEA)和颈动脉支架植入(CAS)。设计/方法:3-round,德尔菲调查被派往欧洲卒中组织成员(n = 390)并选择NA中风神经学家在德克萨斯大学休斯顿中风程序(n = 289)。这些完成调查显示所有响应分解后,欧盟/ NA每个前2轮。大陆具体共识定义\ > 80 \ %的协议。结果:100(15 \ %,其中73 \ %欧盟)完成所有3-Delphi轮,19 \ %所有欧盟vs 9 \ % NA(χ2 = 11.62,p = 0.0007): 76 \ %的男性;69 \ % 1 - 8之间治疗每月新病例的颈动脉狭窄。在最后一轮中,欧盟在7/11报表达成共识,而钠在4/11。百分之九十的欧盟vs 70 \ %的NA(χ2 = 8.09,p = 0.017)不同意,中科院和CEA是等价的sx颈动脉狭窄的治疗方法,并指出,东航优越。欧盟和NA之间仍有显著差异在考虑身体的同侧的中风和死亡\ < 30天作为主要结果(χ2 = 12.18,p = 0.007)。百分之六十九的NA认为有更强的指示CAS在患者CEA \ < 65年sx颈动脉狭窄而55 \ %的欧盟(χ2 = 11.39,p = 0.023)反对这一说法。81 \ %的欧盟和80 \ %的NA说他们有时会{\ textquoteright} {\ textquoteright}推荐东航asx颈动脉狭窄。当被问及他们怎么可能会建议中科院asx颈动脉狭窄,62 \ %的NA说有时{\ textquoteright} {\ textquoteright} vs 60 \ %的欧盟说{\ textquoteright}从未{\ textquoteright}(χ2 = 3.54,p = 0.06)。结论:欧盟更相信东航的优越性,而对于NA,几乎被视为等效的方法。 Areas of lack of consensus may provide direction for future clinical trials.Disclosure: Dr. Balucani has nothing to disclose. Dr. Arnedo has nothing to disclose. Dr. Leys has received research support from Ebewe and Servier. Dr. Mas has nothing to disclose. Dr. Brown has received research support from Reta Lila Weston Trust for Medical Research. Dr. Grotta has received personal compensation for activities with Lundbeck. Dr. Gonzales has nothing to disclose. Dr. Savitz has received personal compensation for activities with Celgene, Aldagen, KM Pharmaceutical, GSK 2 as a consultant. Dr. Savitz has received research support from J\&J, Athersys, Celgene, Genentech (Wake up stroke study), and Aldagen. Dr. Brott has received personal compensation for activities with 3D Communications and Edwards Lifesciences, LLC. Dr. Hacke has nothing to disclose. Dr. Levine has received personal compensation in an editorical capacity for MEDLINK.Thursday, March 21 2013, 2:00 pm-7:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/80/7_Supplement/P07.250}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }